Change in QoL over time in patients with csEVH in the 302 study based on the EORTC QLQ-C30
| Measure, mean ± SD (range) . | Eculizumab (n = 20) . | Ravulizumab (n = 19) . | ||
|---|---|---|---|---|
| Baseline . | Day 183 . | Baseline . | Day 183 . | |
| Global health status/QoL | 62.5 ± 15.4 (41.7-100.0) | 57.1 ± 25.4 (8.3-100.0) | 70.6 ± 18.9 (33.3-100.0) | 70.2 ± 15.3 (33.3-100.0) |
| Physical functioning | 81.3 ± 15.1 (53.3-100.0) | 81.0 ± 15.2 (40.0-100.0) | 82.8 ± 21.7 (33.3-100.0) | 88.4 ± 16.3 (46.7-100.0) |
| Emotional functioning | 81.3 ± 17.9 (41.7-100.0) | 85.8 ± 16.2 (50.0-100.0) | 88.2 ± 15.8 (50.0-100.0) | 91.7 ± 15.7 (41.7-100.0) |
| Cognitive functioning | 83.3 ± 23.6 (0.0-100.0) | 86.7 ± 20.7 (33.3-100.0) | 89.5 ± 18.6 (33.3-100.0) | 92.1 ± 14.0 (50.0-100.0) |
| Social functioning | 76.7 ± 28.3 (0.0-100.0) | 88.3 ± 15.4 (50.0-100.0) | 85.1 ± 26.0 (0.0-100.0) | 92.1 ± 16.1 (50.0-100.0) |
| Role functioning | 80.0 ± 20.0 (33.3-100.0) | 76.7 ± 26.2 (16.7-100.0) | 82.5 ± 28.6 (0.0-100.0) | 90.4 ± 17.0 (50.0-100.0) |
| Nausea and vomiting | 3.3 ± 8.7 (0.0-33.3) | 3.3 ± 10.3 (0.0-33.3) | 7.0 ± 14.0 (0.0-50.0) | 2.6 ± 6.3 (0.0-16.7) |
| Pain | 10.8 ± 19.7 (0.0-66.7) | 12.5 ± 24.7 (0.0-100.0) | 11.4 ± 18.5 (0.0-50.0) | 6.1 ± 11.4 (0.0-33.3) |
| Dyspnea | 26.7 ± 25.6 (0.0-100.0) | 28.3 ± 31.1 (0.0-100.0) | 12.3 ± 19.0 (0.0-66.7) | 8.8 ± 15.1 (0.0-33.3) |
| Insomnia | 23.3 ± 30.8 (0.0-100.0) | 28.3 ± 31.1 (0.0-100.0) | 14 ± 25.6 (0.0-66.7) | 8.8 ± 15.1 (0.0-33.3) |
| Appetite loss | 6.7 ± 17.4 (0.0-66.7) | 16.7 ± 29.6 (0.0-66.7) | 14.0 ± 20.2 (0.0-66.7) | 7.0 ± 14.0 (0.0-33.3) |
| Constipation | 18.3 ± 29.6 (0.0-100.0) | 13.3 ± 27.4 (0.0-100.0) | 8.8 ± 18.7 (0.0-66.7) | 5.3 ± 12.5 (0.0-33.3) |
| Diarrhea | 5.0 ± 12.2 (0.0-33.3) | 1.7 ± 7.5 (0.0-33.3) | 7.0 ± 14.0 (0.0-33.3) | 3.5 ± 10.5 (0.0-33.3) |
| Financial difficulties | 15.0 ± 31.5 (0.0-100.0) | 5.0 ± 12.2 (0.0-33.3) | 8.8 ± 18.7 (0.0-66.7) | 7.0 ± 14.0 (0.0-33.3) |
| Measure, mean ± SD (range) . | Eculizumab (n = 20) . | Ravulizumab (n = 19) . | ||
|---|---|---|---|---|
| Baseline . | Day 183 . | Baseline . | Day 183 . | |
| Global health status/QoL | 62.5 ± 15.4 (41.7-100.0) | 57.1 ± 25.4 (8.3-100.0) | 70.6 ± 18.9 (33.3-100.0) | 70.2 ± 15.3 (33.3-100.0) |
| Physical functioning | 81.3 ± 15.1 (53.3-100.0) | 81.0 ± 15.2 (40.0-100.0) | 82.8 ± 21.7 (33.3-100.0) | 88.4 ± 16.3 (46.7-100.0) |
| Emotional functioning | 81.3 ± 17.9 (41.7-100.0) | 85.8 ± 16.2 (50.0-100.0) | 88.2 ± 15.8 (50.0-100.0) | 91.7 ± 15.7 (41.7-100.0) |
| Cognitive functioning | 83.3 ± 23.6 (0.0-100.0) | 86.7 ± 20.7 (33.3-100.0) | 89.5 ± 18.6 (33.3-100.0) | 92.1 ± 14.0 (50.0-100.0) |
| Social functioning | 76.7 ± 28.3 (0.0-100.0) | 88.3 ± 15.4 (50.0-100.0) | 85.1 ± 26.0 (0.0-100.0) | 92.1 ± 16.1 (50.0-100.0) |
| Role functioning | 80.0 ± 20.0 (33.3-100.0) | 76.7 ± 26.2 (16.7-100.0) | 82.5 ± 28.6 (0.0-100.0) | 90.4 ± 17.0 (50.0-100.0) |
| Nausea and vomiting | 3.3 ± 8.7 (0.0-33.3) | 3.3 ± 10.3 (0.0-33.3) | 7.0 ± 14.0 (0.0-50.0) | 2.6 ± 6.3 (0.0-16.7) |
| Pain | 10.8 ± 19.7 (0.0-66.7) | 12.5 ± 24.7 (0.0-100.0) | 11.4 ± 18.5 (0.0-50.0) | 6.1 ± 11.4 (0.0-33.3) |
| Dyspnea | 26.7 ± 25.6 (0.0-100.0) | 28.3 ± 31.1 (0.0-100.0) | 12.3 ± 19.0 (0.0-66.7) | 8.8 ± 15.1 (0.0-33.3) |
| Insomnia | 23.3 ± 30.8 (0.0-100.0) | 28.3 ± 31.1 (0.0-100.0) | 14 ± 25.6 (0.0-66.7) | 8.8 ± 15.1 (0.0-33.3) |
| Appetite loss | 6.7 ± 17.4 (0.0-66.7) | 16.7 ± 29.6 (0.0-66.7) | 14.0 ± 20.2 (0.0-66.7) | 7.0 ± 14.0 (0.0-33.3) |
| Constipation | 18.3 ± 29.6 (0.0-100.0) | 13.3 ± 27.4 (0.0-100.0) | 8.8 ± 18.7 (0.0-66.7) | 5.3 ± 12.5 (0.0-33.3) |
| Diarrhea | 5.0 ± 12.2 (0.0-33.3) | 1.7 ± 7.5 (0.0-33.3) | 7.0 ± 14.0 (0.0-33.3) | 3.5 ± 10.5 (0.0-33.3) |
| Financial difficulties | 15.0 ± 31.5 (0.0-100.0) | 5.0 ± 12.2 (0.0-33.3) | 8.8 ± 18.7 (0.0-66.7) | 7.0 ± 14.0 (0.0-33.3) |
SD, standard deviation.